The ongoing debate regarding the impact of examined lymph node count on staging and long-term survival of resected non-small cell lung cancer: an editorial review

The ongoing debate regarding the impact of examined lymph node count on staging and long-term survival of resected non-small cell lung cancer: an editorial review

Rian M. Hasson Charles, Shanda H. Blackmon

Division of General Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA

Correspondence to: Shanda H. Blackmon. Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA. Email:

Provenance: This is an invited Editorial commissioned by Section Editor Dr. Monisha Sudarshan (Mayo Clinic, Rochester, Minnesota, USA).

Comment on: Liang W, He J, Shen Y, et al. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected NonSmall-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol 2017;35:1162-70.

Received: 14 March 2018; Accepted: 23 March 2018; Published: 10 May 2018.

doi: 10.21037/vats.2018.04.06

While lymph node (LN) status continues to be one of the most important predictors of prognosis and survival in patients with potentially resectable lung cancer, controversy still remains regarding what is the optimal technique to assess LNs: sampling versus dissection (1-3). Additionally, just how many LNs are required to generate an accurate prognosis has also been a clinical question without a true answer for some time. While emphasis on the number of requisite stations has been discussed in the literature (4-6), the minimum number of LNs required to correctly stage patients at risk for recurrent cancer has not in any significant depth. In the referenced article (7), the authors attempt to quantify the impact of examined LN (ELN) count on precise staging and long-term survival of resected non-small cell lung cancer (NSCLC) using the United States Surveillance, Epidemiology, and End Results (SEER) database and a Chinese Multi-Institutional Registry. Attempts to identify the optimal minimal threshold for ELN counts were then determined.

LN sampling and/or dissection play an important role in determining the extent of disease in lung cancer patients. It not only correctly stages patients and appropriates the need for adjuvant treatment; it portends the risk of disease recurrence and is one of the best predictors of overall survival (OS). The correlation between larger numbers of LNs studied and improved patient survival has been well documented with many other cancers (7), especially in breast and gastrointestinal cancer, and the respective National Comprehensive Cancer Network (NCCN) guidelines recommend the minimal number of LNs needed by either sampling or dissection (8-10). Regarding lung cancer, recommendations regarding the optimal number of nodes remain less defined. Current NCCN guidelines for NSCLC recommend sampling of one or more LN from all mediastinal stations as described using the LN map from the International Association for the Study of Lung Cancer (7,11,12), and provide little guidance as to which method: sampling versus dissection, is best.

When employing LN sampling in lung cancer operations, most centers have followed the protocol described in ACOSOG Z0030 (13), which describes sampling for right lung cancers at stations 2R, 4R, 7, and 10R; and stations 5, 6, 7, and 10L for left lung cancers. Alternatively, LN dissection traditionally involves removal of the nodal packet from the above stations intra-operatively. While there has been much debate whether sampling versus dissection is best (14-16), in general, the overall consensus appears to agree there is no difference in LN sampling versus LN dissection in T1 and T2 tumors (17). However, for more advanced tumors, the recommendations have included performing a mediastinal lymphadenectomy to optimize staging and local control, and guide adjuvant therapy.

The lack of consistency within studies to use either sampling or formal dissection has led to an inability to establish specific guidelines, with the “default” recommendations mentioned above being the norm in most cohorts. Disparities within studies regarding differences in treatment practices and diversity in populations in regards to race, ethnicity, geographic locations and socioeconomic status, have also further limited the ability to transcend results from most studies (even those with large cohorts) to the general population. Liang et al. (7) rightly chose two very large populations, comprised of more than 25 centers in diverse geographic areas that utilized LN dissection combining the surgical count procured by the surgeon with the count procured by the pathologists to create a total LN count. Exclusion of patients with advanced disease (stage IIIB and IV) was also thoughtful given surgery is not the standard of care within those populations. While none of the studies were prospective in nature, the sheer number of patients evaluated helped to overcome bias in charting practices and using data that is retrospective in nature.

Yet, beyond the decision-making process of whether LN sampling versus dissection is more superior, an equally controversial topic is whether mediastinal LN dissection improves survival. On the one hand, a recent meta-analysis of five studies demonstrated two studies that found better survival in patients receiving mediastinal LN dissection than those receiving sampling, while the other three did not (13). On the other hand, one cannot argue the demonstrated benefits of LN dissection presented by Liang et al. (7) demonstrating the proportional increase in N stage with increasing ELN count after adjusting for characteristics including operation performed, T stage, tumor location, and respective histology. Further demonstrating the benefit of LN dissection over sampling included the facts that, (I) the greater number of ELNs was associated with a greater number of positive LNs, especially in patients with node-positive disease, (II) a greater number of ELNs positively correlated with better OS among patients with both node-positive and node-negative disease, and (III) all-cause mortality of patients with at least 16 LNs harvested in node-negative NSCLC was significantly reduced.

Certainly, the stage migration effects appreciated in patients with large samples of LNs cannot be ignored. Still, while the authors attempt to establish a benchmark for LN dissection, there are important questions that remain unanswered. For example, how many of the 16 nodes need to come from each N station? Is there a difference between a majority of N1 nodes versus N2 nodes? Regarding N2 stations, while we know single station disease usually portends a better prognosis than multi-station disease (18,19), is one station more important than others? Specifically, given the suggestion that in other cancers such as breast, full dissection is not always warranted (20) even in the case of node-positive disease (21), is the discovery of one positive LN from a respective N station enough to stop the dissection and appropriately stage and treat the disease? Moreover, do we always need 16 nodes?

To date, the majority of studies evaluating the impact of ELN on precise staging and long-term survival (22-24), still leave many questions. Certainly, the effects that LN sampling and dissection can have on staging and prognosis are well described. As with other cancers (25), the specific advantage of LN dissection to influence stage migration and appropriately guide adjuvant treatment options while providing a more accurate prognosis is immense. The fact that a greater number of ELNs correlated with a higher probability of stage migration is promising. While most studies have either only provided single center experience, with reviews not representing a large demographic; most reviews have faltered due to lack of consistency in LN technique, tumor stage, patient characteristics or pathology acquisition. As endobronchial ultrasound (EBUS) has quickly become the standard first-line technique for LN acquisition, by default, LN sampling has also become slightly more popular. Given this, though future studies with LN dissection may be harder to perform, prospective trails using equally large populations of LN sampling and dissection in populations with similar demographics to see if this results in the same increase in N stage and stage migration would be key to answering this question. Furthermore, maximizing the ability to detect node-positive disease, especially in patients that are thought to be negative, has endless benefits to improving treatment options for lung cancer patients and providing more objective and realistic prognosis estimates at the time of surgery.

In conclusion, it is obvious that further prospective, randomized controlled trials with diverse patient populations that are matched with unified LN sampling protocols are necessary to determine the evolving role of ELN counts in resected NSCLC.


The authors wish to thank Section Editor Monisha Sudarshan for inviting this editorial.


Conflicts of Interest: Dr. SH Blackmon received research grants from TruFreeze and Medtronic, is a speaker for Medtronic and Ethicon, and serves as a consultant for Medtronic and Boston Scientific. Dr. RM Hasson Charles has no conflicts of interest to declare.


  1. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg 2005;80:268-74; discussion 274-5. [Crossref] [PubMed]
  2. Magnanelli G, Scanagatta P, Benato C, et al. Is sampling really effective in staging non-small cell lung cancer? A prospective study. Chir Ital 2006;58:19-22. [PubMed]
  3. Koulaxouzidis G, Karagkiouzis G, Konstantinou M, et al. Sampling versus systematic full lymphatic dissection in surgical treatment of non-small cell lung cancer. Oncol Rev 2013;7:e2. [Crossref] [PubMed]
  4. Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol 2012;7:1798-806. [Crossref] [PubMed]
  5. Watanabe S. Lymph node dissection for lung cancer: past, present, and future. Gen Thorac Cardiovasc Surg 2014;62:407-14. [Crossref] [PubMed]
  6. Tantraworasin A, Saeteng S, Siwachat S, et al. J Impact of lymph node management on resectable non-small cell lung cancer patients. J Thorac Dis 2017;9:666-674. [Crossref] [PubMed]
  7. Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese Multi-Institutional registry. J Clin Oncol 2017;35:1162-70. [Crossref] [PubMed]
  8. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Gastric Cancer, V.2.2013. Available online:
  9. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Colon Cancer, V.2.2013. Available online:
  10. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Breast Cancer, V.4.2014. Available online:
  11. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Lung Cancer, V.4.2014. Available online:
  12. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568-77.
  13. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-70. [Crossref] [PubMed]
  14. Wang Y, Darling GE. Complete mediastinal lymph node dissection versus systemic lymph node sampling in surgical treatment of non-small cell lung cancer: do we have the answer? J Thorac Dis 2017;9:4169-70. [Crossref] [PubMed]
  15. Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis. Eur J Cardiothorac Surg 2017;51:1149-56. [Crossref] [PubMed]
  16. Cox ML, Yang CJ, Speicher PJ, et al. The Role of extent of surgical resection and lymph node assessment for clinical stage I pulmonary lepidic adenocarcinoma: An analysis of 1991 patients. J Thorac Oncol 2017;12:689-96. [Crossref] [PubMed]
  17. Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014;9:e109979. [Crossref] [PubMed]
  18. Misthos P, Sepsas E, Kokotsakis J, et al. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer. Ann Thorac Surg 2008;86:1626-30. [Crossref] [PubMed]
  19. Wang S, Zhou W, Zhang H, et al. Analysis of predictive factors for postoperative survival for non small cell lung carcinoma patients with unexpected mediastinal lymph nodes metastasis. Thorac Cardiovasc Surg 2014;62:126-32. [Crossref] [PubMed]
  20. Bromham N, Schmidt-Hansen M, Astin M, et al. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 2017;1:CD004561. [PubMed]
  21. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017;318:918-26. [Crossref] [PubMed]
  22. Riquet M, Legras A, Mordant P, et al. Number of mediastinal lymph nodes in non-small cell lung cancer: a Gaussian curve, not a prognostic factor. Ann Thorac Surg 2014;98:224-31. [Crossref] [PubMed]
  23. Jeon HW, Moon MH, Kim KS, et al. Extent of removal for mediastinal nodal stations for patients with clinical stage I non-small cell lung cancer: effect on outcome. Thorac Cardiovasc Surg 2014;62:599-604. [Crossref] [PubMed]
  24. D'Andrilli A, Venuta F, Rendina EA. The role of lymphadenectomy in lung cancer surgery. Thorac Surg Clin 2012;22:227-37. [Crossref] [PubMed]
  25. de Widt-Levert L, Tjan-Heijnen V, Bult P, et al. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node. Eur J Surg Oncol 2003;29:216-20. [Crossref] [PubMed]
doi: 10.21037/vats.2018.04.06
Cite this article as: Hasson Charles RM, Blackmon SH. The ongoing debate regarding the impact of examined lymph node count on staging and long-term survival of resected non-small cell lung cancer: an editorial review. Video-assist Thorac Surg 2018;3:21.